Targeting mesothelin in ovarian cancer.
作者信息
Ghafoor Azam, Thomas Anish, Hassan Raffit
机构信息
Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
出版信息
Oncotarget. 2018 Nov 16;9(90):36050-36051. doi: 10.18632/oncotarget.26350.
Abstract
摘要
相似文献
1
Targeting mesothelin in ovarian cancer.
Oncotarget. 2018 Nov 16;9(90):36050-36051. doi: 10.18632/oncotarget.26350.
2
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135.
3
Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer.
Expert Opin Biol Ther. 2021 Aug;21(8):1087-1096. doi: 10.1080/14712598.2021.1869210. Epub 2021 Jan 8.
4
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31. doi: 10.1158/1078-0432.CCR-05-1397.
5
[Mesothelin in ovarian cancer].
Pol Merkur Lekarski. 2013 Sep;35(207):166-70.
6
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20.
7
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877.
8
TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Oncol Rep. 2017 Nov;38(5):3167-3176. doi: 10.3892/or.2017.5941. Epub 2017 Sep 6.
9
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Clin Cancer Res. 2005 May 15;11(10):3814-20. doi: 10.1158/1078-0432.CCR-04-2304.
10
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.
Gene Ther. 2007 Jun;14(12):921-9. doi: 10.1038/sj.gt.3302913. Epub 2007 Mar 22.
引用本文的文献
1
The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review).
Diagnostics (Basel). 2025 May 21;15(10):1289. doi: 10.3390/diagnostics15101289.
2
Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble.
Front Immunol. 2024 Aug 13;15:1407403. doi: 10.3389/fimmu.2024.1407403. eCollection 2024.
3
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.
Front Mol Biosci. 2024 Apr 16;11:1361601. doi: 10.3389/fmolb.2024.1361601. eCollection 2024.
4
The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer.
Cancer Cell Int. 2023 May 27;23(1):104. doi: 10.1186/s12935-023-02948-0.
5
Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.
Diagnostics (Basel). 2023 May 12;13(10):1714. doi: 10.3390/diagnostics13101714.
6
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471.
7
Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Sci Rep. 2021 Apr 7;11(1):7598. doi: 10.1038/s41598-021-87271-2.
8
New Predictive Biomarkers for Ovarian Cancer.
Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465.
9
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.
Cancer Manag Res. 2020 Oct 21;12:10423-10437. doi: 10.2147/CMAR.S249540. eCollection 2020.
10
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML).
Children (Basel). 2020 Feb 10;7(2):12. doi: 10.3390/children7020012.
本文引用的文献
1
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135.
2
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
J Clin Oncol. 2016 Dec;34(34):4171-4179. doi: 10.1200/JCO.2016.68.3672. Epub 2016 Oct 31.
3
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Oncotarget. 2015 May 10;6(13):11694-703. doi: 10.18632/oncotarget.3429.
4
Discovery of mesothelin and exploiting it as a target for immunotherapy.
Cancer Res. 2014 Jun 1;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337. Epub 2014 May 13.
5
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Mol Cancer Ther. 2014 Jun;13(6):1537-48. doi: 10.1158/1535-7163.MCT-13-0926. Epub 2014 Apr 8.
6
Application of mesothelin immunostaining in tumor diagnosis.
Am J Surg Pathol. 2003 Nov;27(11):1418-28. doi: 10.1097/00000478-200311000-00003.
7
8
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40. doi: 10.1073/pnas.93.1.136.
Zotero 插件